Flumazenil is indicated for reversal of sedation from benzodiazepines administered during therapeutic or diagnostic procedures and during induction or maintenance of general anesthesia, as well as for benzodiazepine overdose. Bolus doses of flumazenil are usually adequate to achieve reversal; however, when medical conditions may lead to a prolonged half-life of the benzodiazepine involved, continuous infusion may be warranted. A 67-year-old man with chlordiazepoxide toxicity required a 9-day infusion of flumazenil to prevent resedation and respiratory insufficiency; he initially was admitted to the hospital for alcohol detoxification. Concomitant medical conditions and the metabolism characteristics of each benzodiazepine must dictate the agent of choice. When measures are required to ensure adequate recovery of a patient's respiratory function and mental awareness, such as in patients with benzodiazepine toxicity, consideration of continuous-infusion flumazenil is warranted.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1592/phco.23.14.1513.31941 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of Remimazolam on Transcranial Electrical Motor-evoked Potential in Spine Surgery: A Prospective, Preliminary, Dose-escalation Study.
J Neurosurg Anesthesiol
July 2024
Department of Anesthesiology, Niigata University Medical and Dental Hospital, Niigata.
Article Synopsis
- The study explores the impact of remimazolam, a new anesthetic, on motor-evoked potentials (MEPs) during general anesthesia in patients undergoing spinal fusion surgery.
- Ten adult patients were monitored with varying doses of remimazolam to determine whether higher doses affected MEP amplitude.
- Results indicated no significant difference in MEP amplitude after increasing the dose, suggesting remimazolam may have a minimal impact on these electrical signals in the brain.
Comparison of Remimazolam Tosilate and Propofol Sedation on the Early Postoperative Quality of Recovery in Patients Undergoing Day Surgery: A Prospective Randomized Controlled Trial.
Drug Des Devel Ther
May 2024
Department of Anesthesiology, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, Jiangsu, People's Republic of China.
Purpose: Remimazolam tosilate is a novel ultrafast-acting benzodiazepine that has a rapid emergence even after continuous infusion when using flumazenil. So far, relatively few articles are still focusing on the quality of recovery after general anesthesia with remimazolam, especially in day surgery. This study aimed to compare the early postoperative quality of recovery of remimazolam tosilate with flumazenil and propofol in patients undergoing day surgery.
View Article and Find Full Text PDFComparison of propofol vs. remimazolam on emergence profiles after general anesthesia: A randomized clinical trial.
J Clin Anesth
November 2023
Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyukwan University School of Medicine, Seoul, Republic of Korea. Electronic address:
Study Objective: The emergence profiles in patients undergoing total intravenous anesthesia with either propofol or remimazolam with flumazenil reversal were compared.
Design: A prospective, double-blind, randomized trial.
Setting: An operating room and a post-anesthesia care unit (PACU).
Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification.
Front Psychiatry
March 2021
Department of Internal Medicine, Addiction Unit, Verona University Hospital, Verona, Italy.
An effective approach in the treatment of benzodiazepine (BZD) overdosing and detoxification is flumazenil (FLU). Studies in chronic users who discontinued BZD in a clinical setting suggested that multiple slow bolus infusions of FLU reduce BZD withdrawal symptoms. The aim of this study was to confirm FLU efficacy for reducing BZD withdrawal syndrome by means of continuous elastomeric infusion, correlated to drugs plasma level and patients' compliance.
View Article and Find Full Text PDFAnesthetic management for a patient with myotonic dystrophy with remimazolam.
JA Clin Rep
January 2021
Department of Anesthesia, Ube Industries Central Hospital, 750 Nishikiwa Ube, Yamaguchi, 755-0151, Japan.
Background: Patients with myotonic dystrophy may have increased sensitivity to drugs used for anesthesia. We successfully managed general anesthesia in a patient with myotonic dystrophy using a novel intravenous anesthetic, remimazolam.
Case Presentation: The patient was a 46-year-old man, 169 cm in height, and weighing 60 kg.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!